(Q60209721)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17098084%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

title

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17098084%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17098084%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

author name string

André J Scheen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17098084%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Priscilla Hollander

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17098084%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Michael D Jensen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17098084%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Luc F Van Gaal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17098084%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

RIO-Diabetes Study Group

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17098084%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

language of work or name

English

0 references

publication date

1 November 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17098084%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17098084%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

volume

368

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17098084%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

page(s)

1660-1672

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17098084%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

issue

9548

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17098084%20AND%20SRC:MED&resulttype=core&format=json

NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older

21 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Current management strategies for coexisting diabetes mellitus and obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Type II diabetic subjects lose less weight than their overweight nondiabetic spouses.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Cannabinoid physiology and pharmacology: 30 years of progress.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Leptin-regulated endocannabinoids are involved in maintaining food intake

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

The anti-obesity effect of rimonabant is associated with an improved serum lipid profile

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Development of a brief measure to assess quality of life in obesity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Psychometric evaluation of the impact of weight on quality of life-lite questionnaire (IWQOL-lite) in a community sample.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

The hospital anxiety and depression scale

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

A sharper Bonferroni procedure for multiple tests of significance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Modern statistical methods for handling missing repeated measurements in obesity trial data: beyond LOCF.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Comparison of imputation and modelling methods in the analysis of a physical activity trial with missing outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Criteria for the validation of surrogate endpoints in randomized experiments.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Type 2 diabetes: principles of pathogenesis and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Adiponectin: more than just another fat cell hormone?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Adiponectin and Coronary Heart Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Intentional weight loss and mortality among overweight individuals with diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Comparison of obese NIDDM and nondiabetic women: short- and long-term weight loss.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969571-8

7 January 2021

10.1016/S0140-6736(06)69571-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17098084%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference